NRXS

$6.40+$0.01 (+0.16%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$78.7M

13M shares

52-week range

$2.21 – $9.33

59% from low

Sector

ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS

Exchange

XASE

Change+$0.28

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$10M	+182.7%	$-0.68	$-0.84–$-0.52	—	2
2027	$21M	+112.2%	$-0.06	$-0.06–$-0.06	—	1
2028	$33M	+58.5%	$0.39	$0.39–$0.39	16.4×	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 3 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-11	$-0.32	$-0.19	+40.6%
2026-05-12	$-0.19	$-0.18	+5.3%
2026-03-19	$-0.21	$-0.17	+20.9%
2025-11-10	$-0.20	$-0.24	-20.0%
2025-08-12	$-0.19	$-0.22	-15.8%
2025-05-12	$-0.24	$-0.31	-29.2%
2025-03-20	$0.04	$-0.21	-625.0%
2024-11-12	$1.54	$-0.25	-116.2%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
NRXSNeurAxis, Inc.	$6.56	+4.63%	$82M	—
CLGNCollPlant Biotechnologies Ltd.	$0.30	-5.73%	$4M	—
CVKDCadrenal Therapeutics, Inc. Common Stock	$1.89	+2.45%	$7M	—
ENLVEnlivex Therapeutics Ltd.	$1.92	+4.35%	$32M	—
KLTOKlotho Neurosciences, Inc.	$0.38	-7.10%

Neuraxis, Inc.

Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).

www.neuraxis.com

Employees: 24
IPO / List date: Aug 9, 2023
HQ: CARMEL, IN

Held by traders on TradeandTell

No one on the platform currently holds NRXS.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	76,954	$569.5K

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded NRXS yet.

$NRXS chatter on StockTwits

The Legendary Mayor@BioRichBullish2d
$NRXS Bounceback after pullback?
View on StockTwits ↗
Finnish_boy@Finnish_boyBullish2d
$NRXS Now i stop. CEO mislead me ealier about coverage win. Now i wait the coverage win and then i buy all the shares back. Or drop to $5.25
View on StockTwits ↗
Finnish_boy@Finnish_boyBearish2d
$NRXS CEO: “I’m not happy with these numbers. Nobody’s thrilled with these numbers. Yes, we grew 116%, but the number of patients not being treated... we’re basically treating no one.”
View on StockTwits ↗
Finnish_boy@Finnish_boy2d
$NRXS
View on StockTwits ↗
Finnish_boy@Finnish_boyBearish2d
$NRXS "Practically, this means I expect the company to tap the ATM again in the future." https://mvcinvesting.substack.com/p/neuraxis-nrxs-q2-2026-earnings-review
View on StockTwits ↗
Finnish_boy@Finnish_boyBullish2d
$NRXS If drop to $5.25, i buy some back already even before any additional coverage win. I put alert at $5.5
View on StockTwits ↗
Finnish_boy@Finnish_boyBearish2d
$NRXS I think we see $5.5.. this doesnt sound great. I didnt know earlier about the 70% number.. disappointing. I didnt know enough DD. But i will be back after they announce another big coverage. Q3 revenue will be disappointing.
View on StockTwits ↗
Rays of Sunshine@cleverrox2d
$NRXS NeurAxis Q2: Two Payers, One Number, and the Unit Economics NRXS | Multibagger | Added 8/17/24 @ $3.18 https://microcapopportunities.substack.com/p/neuraxis-q2-two-payers-one-number
View on StockTwits ↗
Finnish_boy@Finnish_boy2d
$NRXS Cash burn increases in H2 accrording CEO. He told that they will be profitable some time after major coverage wins. So lets say Q2 2027. Ramp up is slow bc hospitals have that 70% threshold. When he told that cash burn increases i knew immediately that Q3/Q4 revenue wont be much. Slow ramp ahead. 22 new accounts more in Q2 than Q1. I think they wont get any new coverage by September. Maybe in December or in Q1 2027. I think this is 2027 story. This year i dont expect much. My earlier PT $10 for this year might be too high. Commentary about timing of new coverage was disappointing⬇️i will be back after coverage win. Amazing long-term hold, not sure about near-term.
View on StockTwits ↗
Rays of Sunshine@cleverrox2d
$NRXS NeurAxis to Pour Gasoline on the Fire to Accelerate Growth in Q3 Q2 in Review https://microcapopportunities.substack.com/p/neuraxis-to-pour-gasoline-on-the
View on StockTwits ↗
Finnish_boy@Finnish_boy2d
$NRXS I expect SP to be around $5.0-$8.0 until next earnings.. and next year much higher levels, i think +$15 If Cunha start pumping, +$7 possible near-term
View on StockTwits ↗
Finnish_boy@Finnish_boy2d
$NRXS Not profitability this year. But 2 big coverage wins by Q1 2027
View on StockTwits ↗
Ra's al Ghul@R33dh2d
$NRXS Whoa, someone just bought a huge 100k share lot
View on StockTwits ↗
Finnish_boy@Finnish_boy2d
$NRXS Sold all. Will be back around Q3 earnings.
View on StockTwits ↗
Simon@simoncapitalBearish2d
$NRXS P/S of 12, unprofitable, what’s not to like?
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.